Steven Singer is the chair of the Transactional Department and the Technology Transactions and Licensing Practice Group, as well as a co-chair of the Life Sciences Group. He is also a member of the firm's Management Committee. He joined the firm in 1979.
Practice
Mr. Singer has focused his practice in the life sciences industry for nearly three decades. He has served as counsel for public and private companies in the life sciences sector, including biotechnology, medical device and pharmaceutical companies. His practice focuses on joint ventures and strategic alliances, corporate and securities laws, public offerings and venture capital transactions.
Mr. Singer has worked with the following public company clients, among others: Achillion, Alnylam, Critical Therapeutics, Curis, Idenix, Infinity, Millennium, Momenta and NitroMed. Representative private company clients include Agios, Aveo, Cerulean, Constellation, Generation Health, Hydra, Metamark Diagnostics, Micell and PTC Therapeutics. Mr. Singer has also worked with pharmaceutical companies, including Becton Dickinson, Bristol Myers Squibb, Novartis and Wyeth.
Recent Highlights
- Over the last several years, representation of the following companies in their initial public offerings and follow-on offerings: Achillion, Alnylam, Critical Therapeutics, Curis, Idenix, Infinity, Momenta and NitroMed
- Representation of Alnylam in its alliances with Novartis, Roche and Takeda
- Representation of Infinity Pharmaceuticals in its strategic alliance with Purdue Pharma
- Representation of Adnexus in its acquisition by Bristol Myers Squibb
- Representation of PTC Therapeutics in its alliances with Schering Plough, CV Therapeutics, Pfizer and Genzyme
- Representation of Aveo in its acquisition of product candidates from Kirin and Mitsubishi Pharma
- Representation of the following startup companies in connection with their initial financing rounds: Agios, Coferon, Generation Health, Metamark and Provasculon
- Representation of Paul Capital Partners in its revenue interest-based financing of SpePharm
Professional Activities
Mr. Singer is a member of the American Bar Association, the Biotechnology Industry Organization and the Massachusetts Biotechnology Council.
Honors and Awards
- Recognized as one of the world's leading life sciences lawyers in the 2008, 2010 and 2011 editions of Who's Who Legal: The International Who's Who of Life Sciences Lawyers; also recognized in the 2011 edition of Who's Who Legal: The International Who's Who of Business Lawyers
- Recognized as a national leader in the life sciences: corporate/commercial field in the 2008, 2009, 2010 and 2011 editions of Chambers Global: The World's Leading Lawyers
- Listed in each edition of Chambers USA: America's Leading Lawyers for Business since 2003; recognized each year for his exceptional corporate/M&A practice and also for his life sciences commercial work in 2007, 2008, 2009 and 2011
- Named a "New York Super Lawyer" in the 2011 edition of Metro Edition magazine
- Selected as one of the nation's most highly recommended corporate M&A attorneys in the PLC Cross-Border Mergers and Acquisitions Handbook 2007/08
- Ranked as a leader in the US life sciences commercial and partnering category in the 2006/07, 2007/08 and 2009/2010 editions of the PLC Cross-border Life Sciences Handbook; also highly recommended for his corporate practice in 2006/07 and 2007/08
- Recognized as the "New York Area Biotechnology Lawyer of the Year" in the 2011 edition of The Best Lawyers in America
- Selected by his peers for inclusion in the 2006, 2007, 2008, 2009, 2010, 2011 and 2012 editions of The Best Lawyers in America; recognized for his work in biotechnology law (2006, 2008, 2009, 2010, 2011 and 2012), corporate law (2006, 2007, 2008, 2009, 2010, 2011 and 2012) and M&A law (2008, 2009, 2010, 2011 and 2012)
- Listed as one of the nation's top attorneys in the life sciences commercial and partnering category in the PLC Which Lawyer? Yearbook 2006
- Named a "New England Super Lawyer" (formerly "Massachusetts Super Lawyer") in securities and venture finance in the 2004, 2005, 2006, 2007 and 2008 issues of Boston Magazine
- Recommended in the 2004-2005 edition of the PLC Global Counsel Handbook for both the life sciences corporate partnering and the life sciences corporate & commercial categories
